Latest1 information on COVID-19
©2022 Stanford Medicine
Not Recruiting
Trial ID: NCT01421342
CSP #576 - VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D)
Professor of Psychiatry and Behavioral Sciences (Public Mental Health and Population Sciences)
Inclusion Criteria:
- DSM-IV diagnosis of single or recurrent, non-psychotic, major depressive disorder
- Currently taking a selective serotonin reuptake inhibitor (SSRI) or
serotonin-norepinephrine reuptake inhibitor (SNRI) or mirtazapine for major depressive
disorder
- Need for "next-step" treatment based on documented suboptimal outcome from current
antidepressant treatment for major depressive episode (at least 6 weeks treatment with
a QIDS-C16 >= 16 or at least 8 weeks with a QIDS-C16 >= 11; and at least 3 weeks at a
stable "optimal" dose
- Age: 18 years of age or older
Exclusion Criteria:
- Prior inadequate response after an adequate treatment trial or clear cut intolerance
to either of the study medications (aripiprazole or bupropion)
- Current treatment with bupropion, aripiprazole or any other antipsychotic agent
- Lifetime history of bipolar disorder, schizophrenia, schizoaffective disorder, or
psychosis not otherwise specified
- Current diagnosis of Dementia
- Current diagnosis of an eating disorder or a seizure disorder
- High suicide risk currently requiring acute intervention (other than outpatient
treatment of depression)
- Unstable, serious medical condition or one requiring acute medical treatment, or
anticipation of hospitalization for extended care
- Requiring immediate hospitalization for psychiatric disorders
- Physiologic substance dependence requiring detoxification (excluding nicotine) in the
past 30 days (substance abuse is not an exclusion criteria)
- Taking any concomitant medication that contraindicates any of treatment options or
augmenting agents known to have an antidepressant effect
- Concurrent or recent participation (within the last 30 days) in another conflicting
clinical trial with a mental health, investigational drug, or medical device
intervention
- Female - pregnant or lactating or planning to become pregnant
- Patient was not able or willing to provide informed consent; or changed mind about
participating prior to randomization
- Patient was not referred to the study
drug: Augmenting: Antidepressant + Aripiprazole
drug: Augmenting: Antidepressant + Bupropion-SR
drug: Switching: Bupropion-SR
Not Recruiting
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Trisha Suppes, MD
650-496-2567 Ext. 23655